Background-Recent data suggest that the Pl A2 allele of the platelet glycoprotein IIIa receptor may be a genetic risk factor for cardiovascular disease. We previously reported that the Pl A2 allele was associated with increased platelet aggregability, as indicated by lower epinephrine threshold concentrations. Paradoxically, however, it has been reported that Pl A2 -positive platelets have reduced fibrinogen binding. Because fibrinogen mediates platelet aggregability, we hypothesized that plasma fibrinogen levels may interact with Pl A genotype in modulating platelet aggregability.
M
yocardial infarction results from the formation of a platelet-rich thrombus at the site of a ruptured coronary atherosclerotic plaque. The platelet surface receptor glycoprotein IIb/IIIa (GP IIb/IIIa) plays a key role in the formation of such thrombi by binding with fibrinogen and other ligands, including von Willebrand factor (vWF). The importance of the GP IIb/IIIa receptor has been further supported by recent clinical trials in which GP IIb/IIIa antagonists have been shown to reduce the morbidity and mortality associated with unstable angina, high-risk coronary angioplasty, and acute myocardial infarction.
Weiss and colleagues 1 first reported that patients with acute coronary syndromes were more likely to carry the Pl A2 variant of the GP IIIa receptor than were controls. The risk associated with Pl A2 was especially high for those aged Յ60 years at the time of infarction. Recently Walter and colleagues 2 reported that patients with the Pl A2 variant had an increased risk of coronary stent thrombosis compared with Pl A1 -homozygous individuals. In addition, Pl A2 has been associated with restenosis after coronary stent placement. 3 However, an association between the Pl A2 and cardiovascular disease (CVD) has not been a consistent finding. 4 -10 Recently, we found that the presence of the Pl A2 variant was associated with increased platelet aggregability as indicated by a lower epinephrine threshold concentration. 11 There was also a trend toward Pl A2 being associated with a decreased threshold concentration for ADP, which was directionally consistent with the results seen with epinephrineinduced aggregation. 11 Similar results have been reported with thrombin receptor-activating peptide. 12, 13 Paradoxically, however, Goldschmidt-Clermont et al 14 showed that platelets with the Pl A2 variant bound less exogenous fibrinogen than did the Pl A1 -homozygous platelets when stimulated with ADP. Fibrinogen mediates platelet aggregation by binding to GP IIb/IIIa, and fibrinogen levels influence platelet aggregability. [15] [16] [17] In addition, vWF is a glycoprotein that mediates platelet adhesion by binding with platelet surface receptor GP Ib/IX. This receptor is particularly important in hemostasis and thrombosis at high shear rate. vWF also binds with the platelet GP IIb/IIIa receptor, mediating platelet aggregation. In the current study, we hypothesized that platelet GP IIIa Pl A genotypes may interact with plasma fibrinogen in modulating platelet aggregability. We also evaluated whether plasma vWF levels were associated with platelet aggregability, and if so, whether Pl A genotypes may interact with vWF levels in modulating platelet aggregability.
Methods

Study Population
The study subjects were members of the Framingham Offspring Study, a long-term, prospective evaluation of risk factors for CVD. The study was approved by the Beth Israel Deaconess Medical Center institutional review committee, and all subjects signed a written informed consent form. The design and methodology of the Framingham Offspring Study have been described in detail elsewhere. 18 The participants are natural or adopted children of the original Framingham Heart Study subjects. For this study, we collected data from consecutive subjects examined between April 3, 1991, and June 29, 1995, during the fifth Offspring Study examination cycle. Of the 3799 subjects who attended examination cycle 5, blood samples were collected from 3286 subjects for platelet aggregation analysis. For the present analysis, we excluded subjects who were not members of a sibship (nϭ1298) because linkage analysis was also performed. 11 We also excluded subjects who were receiving an anticoagulant, aspirin, or other antiplatelet drug (nϭ536), subjects in whom genotyping could not be successfully accomplished (nϭ30), and subjects in whom fibrinogen levels were not measured (nϭ82). A total of 1340 subjects fulfilled all inclusion criteria.
Determination of Platelet Aggregability, Fibrinogen, and vWF Levels
Blood samples were obtained in the morning to avoid circadian variation in platelet aggregability. 19 Blood was drawn in 3.8% sodium citrate solution (9:1 vol/vol). Platelet-rich plasma was separated by centrifugation for 10 minutes at 160g. Platelet aggregation was measured according to the method of Born. 20 The aggregation agents tested were epinephrine and ADP in varying concentrations (0.01 to 30 mol/L) and a fixed concentration of arachidonic acid (1.6 mol/L). The lowest concentrations of ADP and epinephrine required to produce a biphasic response with Ͼ50% aggregation (threshold concentration) were determined. Therefore, a lower threshold concentration indicates an increase in platelet aggregability.
Blood for fibrinogen was drawn into 3.8% sodium citrate (9:1, vol/vol), and blood for vWF was collected in EDTA. Plasma was separated by centrifugation for 20 minutes at 2000g and stored at Ϫ80°C for later analysis. Fibrinogen was determined by the Clauss method. vWF antigen was measured by ELISA. The intra-assay coefficients of variation for fibrinogen and vWF in our laboratory were 2.6% and 8.8%, respectively, and the inter-assay coefficients of variation were 4.7% and 10.6%, respectively.
Genotyping
Detailed methods have been reported previously. 11, 21 Polymerase chain reaction results were scored without knowledge of platelet aggregation results. Genotyping was successful in 97% of the samples.
Statistical Analysis
Demographic and clinical characteristics were compared by Student's t tests or 2 tests between genotype groups defined by the presence or absence of the Pl A2 allele. Observed genotype frequencies were compared with the Hardy-Weinberg equilibrium prediction, also using 2 tests. Data on epinephrine and ADP threshold concentrations were log-transformed. Multiple linear regression models were used to analyze platelet aggregability, adjusting for age, sex, body mass index, diabetes, triglycerides, HDL cholesterol, and estrogen replacement status, together with the presence or absence of the Pl A2 allele and fibrinogen quartile (determined separately for each sex). 22, 23 Generalized estimating equation algorithms were used to correct for intra-family correlation. 24 Data on platelet aggregation were expressed as geometric meanϮ95% CI.
Results
Subject Characteristics
The characteristics of the study subjects are shown in Table 1 . Subject characteristics with and without the Pl A2 allele were quite similar, with the exception that cigarette smoking was slightly less common among the Pl A2 -positive genotype subjects (16% versus 20%, Pϭ0.04). Fibrinogen levels were also similar between the 2 groups. The allele frequencies of Pl A1 and Pl A2 were 0.85 and 0.15, respectively. Genotype frequencies were 71.7% for Pl A1 -homozygous, 25.8% for the Pl A1/A2 genotype, and 2.5% for the Pl A2 -homozygous. The genotype frequencies are in accord with the Hardy-Weinberg equilibrium (Pϭ0.65).
Plasma Fibrinogen Levels and Platelet Aggregability
Increased plasma fibrinogen levels were associated with incrementally increased platelet aggregability for epinephrine-induced aggregation and a trend for ADP-induced aggregation, as indicated by decreases in the threshold concentrations for epinephrine and ADP (Pϭ0.002 and 0.07, respectively) ( 
Genotype on Platelet Aggregability
The threshold concentrations for epinephrine-stimulated aggregation decreased with higher fibrinogen levels among the Pl A1 -homozygous subjects, with mean epinephrine threshold concentrations of 1. For ADP-induced aggregation, the threshold concentrations also decreased with increased fibrinogen levels in the Pl A1 -homozygous group, with ADP threshold concentrations of 3.20 (range, 3.02 to 3.39) mol/L, 3.18 (3.01 to 3.37) mol/L, 2.97 (2.80 to 3.16) mol/L, and 2.89 (2.70 to 3.09) mol/L from the lowest quartile to the highest quartile (trend Pϭ0.03) ( Figure 2 ). As seen with epinephrine-induced platelet aggregation, there was no relation found between fibrinogen level and ADP threshold concentration in the subjects with Pl A2 -positive genotype. The respective ADP threshold concentrations were 2.83 (2.58 to 3.10) mol/L, 2.97 (2.71 to 3.26) mol/L, 3.17 (2.87 to 3.49) mol/L, and 2.88 (2.61 to 3.19) mol/L (trend Pϭ0.97). The interaction term assessing fibrinogen-related differences in ADP-induced aggregation between genotypes was statistically significant (Pϭ0.05, multivariate analyses).
Similar results were obtained when we analyzed the relation between fibrinogen levels and platelet aggregability and the interaction between fibrinogen and Pl A genotype on platelet aggregability with fibrinogen as a continuous variable (data not shown).
Platelet aggregation thresholds were modestly but statistically significantly correlated between siblings for epinephrine threshold concentration (rϭ0.245, PϽ0.0001) and for ADP threshold concentration (rϭ0.235, PϽ0.0001). We obtained very similar results for the regression interaction terms relating Pl A genotype with fibrinogen quartile to aggregation thresholds whether the sibship information was included or excluded (data not shown).
There was no significant association between plasma vWF antigen levels and platelet aggregation induced by ADP or epinephrine (Pϭ0.70 and 0.96, respectively; multivariate analyses). Furthermore, vWF did not modify the association between the Pl A genotype and platelet aggregability (data not shown).
Discussion
In a prior Framingham Heart Study investigation, 11 we reported that the Pl A2 allele of the platelet GP IIIa receptor was associated with increased platelet aggregability. In this investigation, we found that higher fibrinogen levels were associated with increased platelet aggregability. In addition, there was an interaction between the Pl A genotype and fibrinogen levels such that the association of greater platelet aggregability with increased fibrinogen levels was significant for the Pl A1/A1 genotype but not for the Pl A2 -positive genotype. Despite these differences, subjects with the Pl A2 -positive genotype had an overall higher platelet aggregability compared with the Pl A1 -homozygous subjects. Studies of twins suggest an important pathogenic role for genetic factors in the pathogenesis of CVD. 25 Although a small proportion of CVD can be attributed to a single gene defect, the nature of additional contributing genetic factors and their interaction with environmental factors remains largely unknown. Because platelets play a central role in acute CVD, it is possible that inherited platelet receptor variants and their interaction with environmental factors may contribute to the onset of CVD.
GP IIIa Polymorphism, Fibrinogen, and Platelet Aggregability
Platelet GP IIb/IIIa is the most abundant platelet receptor. 26 The receptor is highly polymorphic and has long been recognized as having alloantigens, which cause immunemediated platelet destruction. We found that one variant of these polymorphisms, the Pl A2 allele, was associated with heightened platelet aggregability as indicated by a lower epinephrine threshold concentration. 11 Although these findings were supported by studies with thrombin receptoractivating peptide (TRAP) 12, 13 and ADP, 27 the association between the Pl A2 and increased platelet aggregability has not been consistent. For example, Lasne et al 28 found that platelets of Pl A2 -positive genotype needed higher concentrations of TRAP to induce platelet dense granule secretion. Goldschmidt-Clermont et al 14 quantified exogenous fibrinogen binding to platelets of different genotypes. Paradoxically, these investigators found that platelets with the Pl A2 allele bound less exogenous fibrinogen than did platelets that were homozygous for Pl
A1
. However, using the same method, Meiklejohn et al 29 found that the percentage of platelets positive for fibrinogen binding was similar among the Pl A2 -positive platelets and the Pl A1 -homozygous platelets. The reason for the difference in platelet reactivity associated with the Pl A genotype among the various studies is uncertain. The difference is not caused by altered platelet receptor density. 27, 30 One possible explanation is that the mild platelet aggregability change produced by the genetic variation could be masked when a large fixed concentration of agonist is used. 29 In addition, studies with small sample sizes may not have the power to detect differences. 31 In comparison, in our large sample, we titrated the platelet agonists to obtain threshold concentration. 11 In the present study, increased plasma fibrinogen levels in the physiological range were associated with increases in platelet aggregability as indicated by reductions of epinephrine and ADP threshold concentrations. Prior studies similarly reported that an increase of fibrinogen either in the physiological range in the plasma or added extrinsically was associated with a reduction of the median effective dose of ADP. 15, 16 These findings are consistent with fibrinogen's role as ligand for the GP IIb/IIIa receptor. In addition, increased fibrinogen concentrations have also been shown to enhance ADP-and TRAP-induced platelet P-selectin expression. 32 It is therefore possible that platelet reactivity associated with the Pl A polymorphism may be modulated by plasma fibrinogen levels.
Plasma Fibrinogen Levels Interact With Pl
A Polymorphism on Platelet Aggregability
Our results show an interaction between the Pl A genotype and fibrinogen levels on platelet aggregability such that the enhanced platelet aggregability with increased fibrinogen levels were observed in the Pl A1/A1 genotype but not in the Pl A2 -positive genotype. However, the Pl A2 -positive genotype still had an overall higher platelet aggregability compared with the Pl A1 -homozygous even though the Pl A2 -positive genotype platelets bind a smaller 14 or a similar 29 amount of exogenous fibrinogen with the GP IIb/IIIa receptor than do the Pl A1/A1 platelets. Our findings partially explain the conflicting findings regarding the Pl A2 allele and platelet function. [11] [12] [13] [14] [27] [28] [29] 31 Plasma fibrinogen level should be taken into account when platelet reactivity studies are interpreted because fibrinogen level is an important determinant for platelet reactivity and a modulator of platelet aggregability associated with the Pl A genotype. 15, 16, 32 The mechanism for this interaction is unknown. The Pl A antigen system is not in the 2 putative RGD (Arg-Gly-Asp)-binding regions of the GP IIIa (Pl A1 is a leucine and Pl A2 a proline at amino acid position 33). However, according to Calvete, 33 the Pl A system could be brought into immediate proximity with the binding regions by 2 disulfide bonds. Because of the unique structure of proline and its propensity for inducing conformational change, the amino acid substitution could influence the affinity of GP IIb/IIIa receptor for fibrinogen. Thus, the platelet with the Pl A2 variant might have an increased binding with endogenous plasma fibrinogen at basal conditions. If that is the case, fewer GP IIb/IIIa receptors will be available for exogenous fibrinogen after being stimulated as reported by Goldschmidt-Clermont et al. 14 Further study of endogenous and exogenous fibrinogen binding is needed to test the hypotheses. Alternatively, platelets with the Pl A2 allele may have intrinsically increased aggregability as indicated by a lower epinephrine threshold concentration and therefore may be less dependent on plasma fibrinogen levels to achieve a similar degree of platelet aggregation as measured by the Born method. [11] [12] [13] 
Strengths and Limitations of the Study
In a large number of subjects, we obtained genotype status, fibrinogen levels, and platelet aggregability data to evaluate the relation between the Pl A genotype and platelet aggregability and the interaction between the genotype and fibrinogen on platelet aggregability. A detailed risk factor profile was collected and adjusted for potential confounders. However, this cross-sectional study had several limitations. First, our analysis was based on the subset of Framingham subjects in whom both genotype and phenotype data were available. However, the genotype distribution and subject characteristics were similar among subjects excluded from analysis or included in the present analysis (data not shown). Second, we used an in vitro method to evaluate the relation between the Pl A polymorphism, fibrinogen levels, and platelet aggregability. The in vivo significance of our in vitro findings and their clinical relevance need to be evaluated further. Finally, we used epinephrine and ADP threshold concentrations to determine platelet aggregability. Many different methods and parameters have been used to evaluate platelet aggregability, which may influence the results. For example, in one study, 17 increased fibrinogen concentrations led to increased platelet fibrinogen bonding but reduced aggregation velocity. Meade et al 15 found that increased fibrinogen levels were associated with a reduced median effective dose of ADP, a finding similar to our current result, indicating increased platelet aggregability. However, they also reported that increased fibrinogen was associated with a lower maximal response when higher ADP concentration was used, suggesting decreased aggregability.
Implications of the Study
We found that increased plasma fibrinogen levels were associated with increased platelet aggregability, although this association was present for the Pl A1/A1 but not the Pl A2 genotype. Prospective studies are warranted to examine the combined effect of fibrinogen levels and the Pl A polymorphism on incidence of CVD. If individuals with the Pl A2 variant (who have increased platelet aggregability irrespective of fibrinogen levels) or Pl A1 homozygotes with high fibrinogen levels have a higher incidence of CVD, they may benefit from more aggressive measures for prevention and treatment, including therapy with antiplatelet agents.
